Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004

Pediatric Blood & Cancer
A HasslerThomas Lehrnbecher

Abstract

Children with acute myeloid leukemia (AML) and Down syndrome have high survival rates with intensity-reduced chemotherapeutic regimens, although the optimal balance between dose intensity and treatment toxicity has not been determined. We, therefore, characterized infectious complications in children with AML and Down syndrome treated according to AML-BFM 2004 study (ClinicalTrials.gov NCT00111345; amended 2006 for Down syndrome with reduced intensity). Data on infectious complications were gathered from the medical records in the hospital where the patient was treated. Infectious complications were categorized as fever without identifiable source (FUO), or as microbiologically or clinically documented infections. A total of 157 infections occurred in 61 patients (60.5% FUO, 9.6% and 29.9% clinically and microbiologically documented infections, respectively). Almost 90% of the pathogens isolated from the bloodstream were Gram-positive bacteria, and approximately half of them were viridans group streptococci. All seven microbiologically documented episodes of pneumonia were caused by viruses. Infection-related mortality was 4.9%, and all three patients died due to viral infection. Our data demonstrate that a reduced-intensity ch...Continue Reading

References

Apr 26, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
Dec 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kazuko KudoUNKNOWN Japanese Childhood AML Cooperative Study Group
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ben De PauwUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Jun 18, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H SyrjäläUNKNOWN Finnish Leukemia Group
Oct 20, 2010·British Journal of Haematology·Lene Molgaard-HansenUNKNOWN Nordic Society of Paediatric Haematology and Oncology (NOPHO)
Apr 12, 2011·Pediatric Blood & Cancer·Jeffrey W Taub, Yaddanapudi Ravindranath
Aug 11, 2012·Blood·Ursula CreutzigUNKNOWN AML Committee of the International BFM Study Group
Sep 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas LehrnbecherUNKNOWN International Pediatric Fever and Neutropenia Guideline Panel
Jan 3, 2013·Pediatric Blood & Cancer·Katrine Helle JohannsenHenrik Hasle
Mar 13, 2015·The Pediatric Infectious Disease Journal·Susanna FelsensteinJill A Hoffman

❮ Previous
Next ❯

Citations

Mar 8, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Johann K HitzlerUNKNOWN CIBMTR Pediatric Cancer Working Committee
Jun 24, 2017·Blood·Jessica C Shand
May 28, 2019·Leukemia & Lymphoma·Olga Zając-SpychałaJan Styczyński
Oct 20, 2020·American Journal of Medical Genetics. Part a·Stephanie L SantoroGeorge Capone
Mar 12, 2021·Pediatric Blood & Cancer·Azada IbrahimovaKelly D Getz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.